Real-World Clinical, Enviro-Logistical and Economic Implications of Sentinel Lymph Node Biopsy Omission in Early Breast Cancer

The authors investigate the real-world implications of omitting sentinel lymph node biopsy (SLNB) in selected patients with early breast cancer (eBC) who meet specific criteria. Their study finds that approximately 28% of patients qualify for SLNB omission, which not only maintains oncologic safety but also reduces patient time burden, environmental impact, and operating room resource utilization. The findings support the adoption of SLNB omission as a sustainable and value-based approach in surgical oncology.